Ochroconis are dematiaceous fungi generally found in the environment but having the ability to infect humans, dogs, cats, poultry, and fish. This study presents the antifungal susceptibility patterns of these fungi at the species level. Forty strains originating from clinical and environmental sources were phylogenetically identified at the species level by using sequences of the ribosomal DNA internal transcribed spacer (rDNA ITS). In vitro antifungal susceptibility testing was performed against eight antifungals, using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. The geometric mean MICs for amphotericin B (AMB), flucytosine (5FC), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), and posaconazole (POS) and minimum effective concentrations (MECs) for caspofungin (CAS) and anidulafungin (AFG) across the Ochroconis and Verruconis species were as follows, in increasing order. For Verruconis species, the values (g/ml) were as follows: AFG, 0.04; POS, 0.25; ITC, 0.37; AMB, 0.50; CAS, 0.65; VRC, 0.96; 5FC, 10.45; and FLC, 47.25. For Ochroconis species, the values (g/ml) were as follows: AFG, 0.06; POS, 0.11; CAS, 0.67; VRC, 2.76; ITC, 3.94; AMB, 5.68; 5FC, 34.48; and FLC, 61.33. Antifungal susceptibility of Ochroconis and Verruconis was linked with phylogenetic distance and thermotolerance. Echinocandins and POS showed the greatest in vitro activity, providing possible treatment options for Ochroconis and Verruconis infections.
R ecently, by combined molecular phylogeny, morphology, and ecology, the taxonomy of the Ochroconis lineage was revised (1) . Two genera were recognized: Ochroconis and Verruconis. Within melanized filamentous fungi, members of Ochroconis and Verruconis are morphologically exceptional by having sympodial conidiogenesis with rhexolytic conidial dehiscence (2) . However, both genera are melanized, oligotrophic, and regularly encountered in indoor environments, in soil, or in heated habitats, and some species have the ability to cause superficial, cutaneous, and systemic infections in immunocompromised patients (3) (4) (5) (6) .
Verruconis species are thermophilic, with Verruconis gallopava occurring in hot environments, such as thermal soils, broiler house litter, hot springs, and self-heated waste (1) . Pathology in Verruconis is restricted to V. gallopava, which is the main agent of human brain infections and is responsible for encephalitis in poultry and wild birds (7) (8) (9) (10) (11) (12) (13) (14) (15) , dogs (16) , and cats (17) . In contrast, Ochroconis species are mesophilic saprobes, with an optimum growth temperature between 15 and 30°C and an inability to grow at 37°C, which occasionally infect cold-blooded vertebrates (1, 18) . Only a single infection was noted in a warm-blooded animal, i.e., a subcutaneous lesion in a cat (19) , while the first subcutaneous human infection due to Ochroconis tshawytschae was recently reported (20) .
Despite significant medical and veterinary importance, little is known regarding the species-specific antifungal susceptibility profiles of Verruconis and Ochroconis species. The polyene agents exert their antifungal activity via binding to ergosterol in the fungal cell membrane. This disrupts cell permeability and results in rapid cell death. Flucytosine exerts antifungal activity via inhibition of both DNA synthesis and protein synthesis in the fungal cell. Azole agents exert their antifungal activity by blocking the demethylation of lanosterol, thereby inhibiting ergosterol synthesis. The mechanism of activity of the echinocandins is inhibition of the production of (1,3)-␤-D-glucan, an essential component in the fungal cell wall (21) . We therefore investigated the in vitro susceptibilities of a large collection of clinical and environmental isolates of thermophilic and mesophilic species to eight antifungal drugs.
(Some of these results were presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 10 to 13 September 2013.)
MATERIALS AND METHODS
Fungal strains. Strains used in this study are listed in Table 1 , with origin, identification number, and clinical data for each isolate. In total, 40 strains from clinical and environmental sources were used. Lyophilized fungal strains were obtained from the reference collection of the CBS-KNAW Fungal Biodiversity Centre (CBS, Utrecht, The Netherlands) and selected according to their historical pathogenicity. In addition, the representative type species of saprophytic strains were used for environmental isolates of both genera (Table 1) . All isolates were cultured on malt extract agar (MEA) at 24°C for 14 days. Morphological identifications were confirmed by sequence-based analysis of the internal transcribed spacer (ITS) of the ribosomal DNA (rDNA) region, as described previously (1) . Briefly, sequences were edited using the SeqMan tool of Lasergene software (DNAStar Inc., Madison, WI) and then aligned interactively using Ward's averaging in the BioNumerics package v. 4.61 (Applied Maths, Kortrijk, Belgium). The ITS sequences were finally aligned with the program MUSCLE (www.ebi.ac.uk/Tools/msa/muscle), and the aligned sequences were adjusted using BioEdit v. 7.0.5.2. The ITS data set was then analyzed by use of MEGA5 software (22) , in which the Tamura three-parameter model with gamma distribution (T92ϩG) was searched as the best model. The maximum likelihood (ML) heuristic method with 1,000-replicate bootstrapping and the maximum parsimony (MP) method with 1,000replicate bootstrapping were performed for tree reconstructions and phylogeny tests. To strongly confirm the analyses, the ML method with the approximate likelihood ratio test (aLRT) was also performed with PhyML (23 (24) . The final concentrations of the antifungal agents ranged from 0.016 to 16 g/ml for amphotericin B (AMB), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), posaconazole (POS), caspofungin (CAS), and anidulafungin (AFG). Flucytosine (5FC) was assayed over a 2-fold concentration range from 0.064 to 64 g/ml. Reading of results was performed using a reading mirror and a microtitration plate spectrophotometric reader (Anthos htIII; Anthos Labtec Instruments, Salzburg, Austria).
Ochroconis isolates were incubated at 25°C, and Verruconis isolates were incubated at 37°C. Agitation of plates was not used. The MICs of AMB, FLC, 5FC, ITC, VRC, and POS were determined visually with an inverted mirror by comparison of growth in the wells containing the drug and that of the drug-free control. The minimum effective concentrations (MECs) of CAS and AFG were read with a plate microscope (Olympus SZX9; Olympus Nederland, Zoeterwoude, The Netherlands) at a magnification of ϫ25 to ϫ50. The MEC was defined as the lowest concentration at which abnormal, short, and branched hyphal clusters were observed, in contrast to the long, unbranched hyphal elements that were seen in the growth control well.
Paecilomyces variotii (ATCC 22319), Candida parapsilosis (ATCC 22019) and Candida krusei (ATCC 6258) were used as quality controls in all experiments. The ranges and geometric means (GM) of the MICs and MECs were determined for each species and drug after 48 to 168 h of incubation. Furthermore, the MIC 50 s and MIC 90 s for the isolates were calculated by use of the criteria for MIC determinations described above. The MIC 50 and MIC 90 values were calculated for those species with 10 or more isolates. If the MIC values of the replicates were different, the GM values of the replicates were used for comparison with other isolates. All experiments were performed in three independent replicates with each strain on different days.
Statistical analysis. Data analyses were performed by using GraphPad Prism, version 5.0, for Windows (GraphPad Software, San Diego, CA). MIC/MEC distributions between isolates were compared by using the Mann-Whitney-Wilcoxon test. Statistical significance was defined as having a P value of Յ0.05 (two-tailed).
RESULTS
All strains were identified to the species level by sequence-based analysis and tested against eight antifungal compounds. Two genera have been recognized based on molecular phylogeny, viz., Verruconis and Ochroconis. In Fig. 1 , data are summarized for relevant species, displaying their mutual phylogenetic distances, interspecies variability according to temperature tolerance, and antifungal susceptibility profiles per species. GM MICs, MIC ranges, and MIC 50 and MIC 90 distributions for eight antifungal agents are summarized in Table 2 .
Overall, visual and spectrophotometric readings gave similar results for the MIC and MEC endpoints. The GM MICs for AMB, 5FC, FLC, ITC, VRC, and POS and the MEC values for CAS and AFG across the genera in this study are shown below, in increasing order. For Verruconis, the values (g/ml) were as follows: AFG, 0.04; POS, 0.25; ITC, 0.37; AMB, 0.50; CAS, 0.65; VRC, 0.96; 5FC, 10.45; and FLC, 47.25. For Ochroconis, the values (g/ml) were as follows: AFG, 0.06; POS, 0.11; CAS, 0.67; VRC, 2.76; ITC, 3.94; AMB, 5.68; 5FC, 34.48; and FLC, 61.33. The widest ranges were seen for FLC (range, 1 to Ն64 g/ml) and 5FC (range, 0.5 to 64 g/ml). The highest GM MICs were 47.25 g/ml, for FLC, followed by 10.45 g/ml, for 5FC. AMB MICs ranged from 0.125 to Ͼ16 g/ml, and ITC had a MIC range of Ͻ0.016 to Ͼ16 g/ml. POS exhibited potent activity against all strains, with MICs ranging from Ͻ0.0016 to 4 g/ml, while the GM MIC of VRC (0.96 g/ml) was 2 log 2 dilution steps less potent than that of POS (0.25 g/ml) against thermotolerant strains and 6 log 2 dilution steps less active than in the Ochroconis species (2.76 g/ml VRC versus 0.11 g/ml POS). Notably, Ochroconis isolates had higher MICs of AMB, 5FC, FLC, ITC, and VRC than those for Verruconis strains. The two echinocandins showed susceptible profiles in their MECs. In most cases, AFG had a higher activity than that of CAS (AFG MEC of 0.04 g/ml versus 0.65 g/ml CAS against Verruconis strains, and AFG MEC of 0.06 g/ml versus 0.67 g/ml CAS against Ochroconis species). In addition, various susceptibility profiles were demonstrated within the genera. For Ochroconis, the triazole derivatives ITC and VRC and AMB offered significantly (P Յ 0.05) higher susceptible profiles for O. mirabilis than for the other species. However, 5FC and FLC were found to be less active against V. gallopava than against V. calidifluminalis (P Յ 0.05).
DISCUSSION
The genus Ochroconis was recently revised and currently contains 13 species (1). Species accepted within the lineage, within the order Venturiales, were keyed out on the basis of molecular phylogeny and phenotypic and physiologic characteristics. A new genus, Verruconis, was proposed for the neurotropic opportunist Ochroconis gallopava and its close relatives.
Notably, thermotolerance has a significant impact on the virulence potential of Ochroconis and Verruconis species, as shown previously in other melanized fungi. Species able to grow at temperatures of 37°C or above (e.g., Cladophialophora bantiana, Exophiala dermatitidis, and Exophiala jeanselmei) (25) may cause systemic or disseminated infections in mammals. The black yeast Exophiala dermatitidis has a maximum growth temperature of 42 to 45°C and has a natural habitat in association with birds and bats, which have a body temperature well above that of humans (26, 27) . Mesophilic species with maximum growth temperatures of 27 to 33°C are restricted to cold-blooded vertebrates (25) or, occasionally, invertebrates (28, 29) .
The availability of in vitro susceptibility profiles according to the latest taxonomic studies of Ochroconis and Verruconis species (1) is scant. Our study provides the first antifungal susceptibility data on a large set of clinical and environmental strains from a wide range of sources and origins. Our results indicate that thermotolerance has a significant impact on the antifungal susceptibility of Ochroconis and Verruconis species. Both thermotolerant and mesophilic species had susceptibility profiles with a uniform pattern of low MICs for POS, AFG, and CAS. VRC, AMB, and ITC showed efficacy against Verruconis species, with 1-, 3-, and 4-log 2 less susceptibility, respectively, than Ochroconis species. The majority of strains demonstrated high MICs for 5FC and FLC, indicating poor activity of these drugs against the pathogens. Both echinocandins were found to have potent in vitro activity against Ochroconis species. This matches previously reported data for CAS, with a MEC of 0.25 g/ml against Ochroconis tshawytschae (20) and 0.03 to 1 g/ml against Verruconis gallopava (30, 31) . This is in contrast with previously published data on most melanized fungi, which appear to be tolerant to echinocandins, probably due to the presence of melanin, which prevents penetration of antifungals into fungal cells (32) . Nevertheless, O. mirabilis demonstrated less susceptibility to ITC, VRC, and AMB (P Յ 0.05) than the other Ochroconis species, and V. calidifluminalis was more susceptible to 5FC and FLC than V. gallopava (P Յ 0.05).
Given that the echinocandins and the triazole POS showed the highest in vitro activity against thermotolerant and mesophilic species, a possible treatment option for Ochroconis and Verruconis infections in both warm-blooded (human) and cold-blooded animals may be provided. The triazole POS is an expanded-spectrum triazole with fungicidal activity against a wide spectrum of molds, including Aspergillus species and members of the Mucorales, as well as enhanced activity against Candida and other yeasts (33) . The echinocandins represent the newest class of antifungals that exhibit fungicidal activity against many Candida species, making this drug class a desirable alternative to the azole agents, which exhibit only static activity against yeasts. Because mammalian cells have no cell wall, the echinocandins have very few adverse effects in humans (33) .
In general, the divergent antifungal profiles of the Verruconis and Ochroconis genera and the interspecies variability observed (34), several studies suggest that POS and ITC may provide optimal therapies for Ochroconis infection, followed by AMB and VRC, and that 5FC and FLC are the least effective drugs (6, 30, 31, 35, 36) , which is in agreement with the in vitro results of the present study. Treatment of Verruconis infections with VRC is supported by in vitro results, and it proved to be active in a chronic granulomatous disease (CGD) patient (34) . VRC has an optimal oral bioavailability and penetration to the blood-brain barrier, indicating its use for cerebral infections. In some cases of V. gallopava infections, AMB was also used successfully in empirical antifungal therapy (37) . However, further studies are required to establish the optimal treatment. In addition, as recommended for other fungal infections, supportive management strategies, such as surgical excision of lesions, are recommended whenever feasible (34) . Early diagnosis and treatment are also mandatory in order to avoid dissemination to the brain, which carries a very poor prognosis (20) .
In conclusion, although there are no clinically defined breakpoints for Verruconis and Ochroconis species and the lack of interpretative breakpoints makes MICs difficult to interpret, antifungal susceptibility testing can be helpful in guiding clinical management of patients with these infections. Based on the data presented in the current study, POS and echinocandins were the antimycotics with the best overall activity, having broad-spectrum activity against both thermotolerant and mesophilic species. The apparently good penetration of POS into the central nervous system (CNS), with the MIC falling well below the serum levels achievable with standard dosing regimens (38) , combined with excellent in vitro data (39) and activity in animal models (40) (41) (42) (43) , supports the use of POS for difficult-to-treat disseminated brain infections. In the clinical setting, POS has been used successfully in cases of cerebral and disseminated phaeohyphomycosis (44, 45) . In addition, POS and VRC are routinely recommended for treatment, prophylaxis, and salvage therapy of life-threatening fungal infections, such as Aspergillus diseases. POS also has a label indication for the treatment of less common infections, including chromoblastomycosis, mycetoma, and coccidioidomycosis. Therefore, standard dosing regimens and provisional target concentrations used for the prevention or treatment of invasive fungal infections (46) might be optimal tentative suggestions for Verruconis and Ochroconis infections. 
